PL2651975T3 - Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania - Google Patents

Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania

Info

Publication number: PL2651975T3
Authority: PL; Poland
Prior art keywords: denga; seroty; respectivity; application; monoclonal antibodies
Prior art date: 2010-12-14

Application number

PL11848839T

Other languages

English (en)

Inventor

Paul Anthony Macary

Ee Ping Evelyn Teoh

Brendon John Hanson

En Wei Teo

Angeline Pei Chiew Lim

Mah Lee Mary Ng

Shee Mei Lok

Petra Eveliina Kukkaro

Original Assignee

Dso Nat Laboratories

Nat Univ Singapore

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-14

Filing date

2011-12-14

Publication date

2018-04-30

2011-12-14 Application filed by Dso Nat Laboratories, Nat Univ Singapore filed Critical Dso Nat Laboratories

2018-04-30 Publication of PL2651975T3 publication Critical patent/PL2651975T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL11848839T 2010-12-14 2011-12-14 Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania PL2651975T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42308510P	2010-12-14	2010-12-14
EP11848839.4A EP2651975B1 (en)	2010-12-14	2011-12-14	Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
PCT/SG2011/000436 WO2012082073A1 (en)	2010-12-14	2011-12-14	Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Publications (1)

Publication Number	Publication Date
PL2651975T3 true PL2651975T3 (pl)	2018-04-30

Family

ID=46244986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11848839T PL2651975T3 (pl)	2010-12-14	2011-12-14	Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania

Country Status (28)

Country	Link
US (2)	US9376486B2 (pl)
EP (1)	EP2651975B1 (pl)
JP (2)	JP6483337B2 (pl)
KR (2)	KR101904232B1 (pl)
CN (1)	CN103534270B (pl)
AU (2)	AU2011341744B2 (pl)
BR (1)	BR112013015129B1 (pl)
CA (1)	CA2821268C (pl)
CO (1)	CO6801636A2 (pl)
CY (1)	CY1119854T1 (pl)
DK (1)	DK2651975T3 (pl)
EA (1)	EA201390874A1 (pl)
ES (1)	ES2644236T3 (pl)
HR (1)	HRP20171580T1 (pl)
HU (1)	HUE035609T2 (pl)
IL (1)	IL226957B (pl)
LT (1)	LT2651975T (pl)
MX (1)	MX348152B (pl)
MY (2)	MY201732A (pl)
PH (2)	PH12013501242B1 (pl)
PL (1)	PL2651975T3 (pl)
PT (1)	PT2651975T (pl)
RS (1)	RS56737B1 (pl)
SG (2)	SG10201510111PA (pl)
SI (1)	SI2651975T1 (pl)
SM (1)	SMT201700477T1 (pl)
WO (1)	WO2012082073A1 (pl)
ZA (1)	ZA201304459B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008304748C1 (en)	2007-09-26	2014-06-12	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
SMT201700477T1 (it) *	2010-12-14	2018-01-11	Nat Univ Singapore	Anticorpi monoclonali umani con specificita’ per proteina e del virus dengue sierotipo 1 e suoi usi
CN108912215A (zh) *	2012-04-02	2018-11-30	北卡罗来纳-查佩尔山大学	用于登革病毒表位的方法和组合物
WO2014064707A1 (en) *	2012-10-26	2014-05-01	International Centre For Genetic Engineering And Biotechnology	Pichia pastoris -expressed dengue virus like particles
EP3013852B1 (en) *	2013-06-26	2019-06-19	The University of North Carolina at Chapel Hill	Compositions for dengue virus vaccines and their use
US9212217B2 (en)	2014-02-11	2015-12-15	Visterra, Inc.	Antibody molecules to dengue virus and uses thereof
CN114773470A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI763660B (zh)	2016-03-25	2022-05-11	美商威特拉公司	登革病毒的抗體分子之配方設計
TWI693940B (zh)	2016-08-05	2020-05-21	日商中外製藥股份有限公司	Ｉｌ-８相關疾病之治療用或預防用組成物
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3093729A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US10526398B2 (en) *	2018-06-12	2020-01-07	National Defense Medical Center	Anti-dengue virus antibodies and applications thereof
US12161890B2 (en)	2018-08-07	2024-12-10	Cz Biohub Sf, Llc	Antibodies against dengue virus and related methods
US12600752B2 (en)	2019-11-20	2026-04-14	The University Of North Carolina At Chapel Hill	Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
WO2021127017A1 (en) *	2019-12-16	2021-06-24	La Jolla Institute For Immunology	Combinations of flavivirus proteins, peptide sequences, epitopes, and methods and uses thereof
CN117157524A (zh) *	2020-10-07	2023-12-01	赛诺菲巴斯德有限公司	改良的诊断测试
WO2022161597A1 (en) *	2021-01-26	2022-08-04	Eth Zurich	Method for rapid identification of cross-reactive and/or rare antibodies
WO2022162009A1 (en)	2021-01-26	2022-08-04	Eth Zurich	Method for rapid identification of cross-reactive and/or rare antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de)	1982-06-26	1983-12-29	Basf Ag, 6700 Ludwigshafen	Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5651991A (en)	1987-10-28	1997-07-29	Nippon Shinyaku Co. Ltd.	Drug carriers
US5994392A (en)	1988-02-26	1999-11-30	Neuromedica, Inc.	Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko)	1992-08-14	1994-02-21	김형술	세탁물 건조기
EP0640622B1 (en)	1993-02-26	2000-08-09	Drug Delivery System Institute, Ltd.	Polysaccharide derivative and drug carrier
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
FI955320A7 (fi)	1994-03-07	1995-11-24	Univ Michigan	Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
US5786387A (en)	1994-03-23	1998-07-28	Meiji Seika Kabushiki Kaisha	Lipid double-chain derivative containing polyoxyethylene
JP3699141B2 (ja)	1994-09-24	2005-09-28	伸彦由井	超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en)	1994-09-26	1996-02-13	General Electric Company	Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de)	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en)	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US6106866A (en)	1995-07-31	2000-08-22	Access Pharmaceuticals, Inc.	In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en)	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
DK1141028T3 (da)	1998-12-23	2010-05-25	Pfizer	Humane monoklonale antistoffer til CTLA-4
IL148079A0 (en)	1999-08-24	2002-09-12	Medarex Inc	Human ctla-4 antibodies and compositions containing the same
US20040126829A1 (en)	2001-12-18	2004-07-01	Hildebrand William H.	Anti-HLA assay and methods
EP1532175B1 (en)	2002-03-22	2012-10-17	Aprogen, Inc.	Humanized antibody and process for preparing the same
CA2894300A1 (en)	2003-12-08	2005-06-23	The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services	Monoclonal antibodies that bind or neutralize dengue virus
US7981431B2 (en) *	2007-06-08	2011-07-19	National Health Research Institutes	Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use
GB0724065D0 (en)	2007-12-10	2008-01-16	Sparrow Paul A	A spirit level
EP2294192A4 (en)	2008-06-09	2011-11-23	Jolla Inst Allergy Immunolog	COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)
MX2011003588A (es) *	2008-10-13	2011-10-14	Inst Research In Biomedicine	Anticuerpos neutralizadores del virus del dengue y uso de los mismos.
SG173482A1 (en)	2009-02-10	2011-09-29	Univ Nanyang Tech	Antibodies for diagnosis and treatment of flaviviral infections
SMT201700477T1 (it)	2010-12-14	2018-01-11	Nat Univ Singapore	Anticorpi monoclonali umani con specificita’ per proteina e del virus dengue sierotipo 1 e suoi usi

2011
- 2011-12-14 SM SM20170477T patent/SMT201700477T1/it unknown
- 2011-12-14 EP EP11848839.4A patent/EP2651975B1/en active Active
- 2011-12-14 JP JP2013544435A patent/JP6483337B2/ja not_active Expired - Fee Related
- 2011-12-14 KR KR1020177026209A patent/KR101904232B1/ko not_active Expired - Fee Related
- 2011-12-14 AU AU2011341744A patent/AU2011341744B2/en not_active Ceased
- 2011-12-14 EA EA201390874A patent/EA201390874A1/ru unknown
- 2011-12-14 WO PCT/SG2011/000436 patent/WO2012082073A1/en not_active Ceased
- 2011-12-14 SG SG10201510111PA patent/SG10201510111PA/en unknown
- 2011-12-14 MX MX2013006710A patent/MX348152B/es active IP Right Grant
- 2011-12-14 CA CA2821268A patent/CA2821268C/en active Active
- 2011-12-14 RS RS20171031A patent/RS56737B1/sr unknown
- 2011-12-14 HU HUE11848839A patent/HUE035609T2/hu unknown
- 2011-12-14 HR HRP20171580TT patent/HRP20171580T1/hr unknown
- 2011-12-14 PL PL11848839T patent/PL2651975T3/pl unknown
- 2011-12-14 PH PH1/2013/501242A patent/PH12013501242B1/en unknown
- 2011-12-14 LT LTEP11848839.4T patent/LT2651975T/lt unknown
- 2011-12-14 MY MYPI2017000896A patent/MY201732A/en unknown
- 2011-12-14 US US13/993,983 patent/US9376486B2/en active Active
- 2011-12-14 BR BR112013015129-3A patent/BR112013015129B1/pt not_active IP Right Cessation
- 2011-12-14 DK DK11848839.4T patent/DK2651975T3/en active
- 2011-12-14 SG SG2013045745A patent/SG191155A1/en unknown
- 2011-12-14 MY MYPI2013002206A patent/MY166537A/en unknown
- 2011-12-14 CN CN201180066887.9A patent/CN103534270B/zh not_active Expired - Fee Related
- 2011-12-14 ES ES11848839.4T patent/ES2644236T3/es active Active
- 2011-12-14 SI SI201131313T patent/SI2651975T1/en unknown
- 2011-12-14 PT PT118488394T patent/PT2651975T/pt unknown
- 2011-12-14 KR KR1020137018382A patent/KR101781546B1/ko not_active Expired - Fee Related
2013
- 2013-06-13 IL IL226957A patent/IL226957B/en active IP Right Grant
- 2013-06-18 ZA ZA201304459A patent/ZA201304459B/en unknown
- 2013-07-12 CO CO13165679A patent/CO6801636A2/es active IP Right Grant
2016
- 2016-06-01 US US15/170,838 patent/US10294293B2/en active Active
- 2016-12-08 AU AU2016269515A patent/AU2016269515A1/en not_active Abandoned
2017
- 2017-06-08 PH PH12017501075A patent/PH12017501075B1/en unknown
- 2017-10-20 JP JP2017203328A patent/JP2018046835A/ja not_active Withdrawn
- 2017-11-08 CY CY20171101173T patent/CY1119854T1/el unknown

Also Published As

Publication number	Publication date
CO6801636A2 (es)	2013-11-29
PT2651975T (pt)	2017-11-14
MX2013006710A (es)	2014-09-25
HUE035609T2 (hu)	2018-05-28
MY166537A (en)	2018-07-10
CA2821268C (en)	2021-06-15
JP6483337B2 (ja)	2019-03-13
EP2651975A4 (en)	2014-05-21
KR101904232B1 (ko)	2018-10-05
PH12013501242A1 (en)	2013-08-12
IL226957B (en)	2020-03-31
KR20170110159A (ko)	2017-10-10
KR101781546B1 (ko)	2017-09-26
EA201390874A1 (ru)	2013-12-30
DK2651975T3 (en)	2017-10-30
SG191155A1 (en)	2013-07-31
HRP20171580T1 (hr)	2018-01-26
WO2012082073A1 (en)	2012-06-21
CN103534270B (zh)	2017-03-08
PH12017501075B1 (en)	2019-11-29
LT2651975T (lt)	2018-02-12
PH12013501242B1 (en)	2019-01-30
US20130259871A1 (en)	2013-10-03
US9376486B2 (en)	2016-06-28
ES2644236T3 (es)	2017-11-28
AU2011341744B2 (en)	2016-09-08
RS56737B1 (sr)	2018-03-30
CA2821268A1 (en)	2012-06-21
SMT201700477T1 (it)	2018-01-11
BR112013015129B1 (pt)	2022-11-16
ZA201304459B (en)	2019-11-27
EP2651975B1 (en)	2017-08-09
US10294293B2 (en)	2019-05-21
KR20140019777A (ko)	2014-02-17
BR112013015129A2 (en)	2018-10-09
JP2014502839A (ja)	2014-02-06
CY1119854T1 (el)	2018-06-27
MY201732A (en)	2024-03-14
JP2018046835A (ja)	2018-03-29
PH12017501075A1 (en)	2018-02-12
SI2651975T1 (en)	2018-03-30
AU2011341744A1 (en)	2013-07-18
AU2016269515A1 (en)	2017-01-05
US20170029489A1 (en)	2017-02-02
CN103534270A (zh)	2014-01-22
SG10201510111PA (en)	2016-01-28
MX348152B (es)	2017-06-02
EP2651975A1 (en)	2013-10-23

Publication	Publication Date	Title
PL2651975T3 (pl)	2018-04-30	Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
IL285226B (en)	2022-10-01	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL272831A (en)	2020-04-30	Meditopes and meditope-binding antibodies and uses thereof
IL262073B (en)	2020-11-30	Antibody drug conjugates (adc) that bind to 191p4d12 proteins
HRP20170983T1 (hr)	2017-09-22	Pripravci s visokom koncentracijom antitijela
IL244801B (en)	2020-05-31	Human il-23 antigen binding proteins
IL254004A0 (en)	2017-10-31	Monoclonal antibodies to progastrin and their uses
IL222507B (en)	2019-05-30	Heterodimeric antibody fc-containing proteins and methods for production thereof
HRP20181811T1 (hr)	2018-12-28	Zbirka sljedova protutijela i njezina upotreba
PT2424896E (pt)	2015-11-30	Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
HUE053720T2 (hu)	2021-07-28	ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2408921A4 (en)	2012-10-10	MODIFICATION OF CXCR4 USING MODIFIED ZINC FINGER PROTEINS
BR112015003838A2 (pt)	2017-07-04	formulações de anticorpo e proteína
CO7020851A2 (es)	2014-08-11	Proteínas y péptidos modificados
HUE043355T2 (hu)	2019-08-28	LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében
HUE057004T2 (hu)	2022-04-28	CD277 elleni antitestek és alkalmazásaik
PT2580240T (pt)	2019-03-29	Anticorpos as100a4 e utilizações terapêuticas dos mesmos
IL210768B (en)	2018-02-28	Antibodies targeting complement protein c5 and compositions comprising them
IL226427A0 (en)	2013-07-31	Anti ccr4 antibodies and uses thereof
IL225389A0 (en)	2013-06-27	Antibody compositions and methods of use
PL2776460T3 (pl)	2018-10-31	Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
BR112015003032A2 (pt)	2017-12-12	anticorpos anti-jagged e métodos de utilização'.
IL223665B (en)	2020-01-30	Human antibodies to human cytomegalovirus (cmv) gb protein
EP2650367A4 (en)	2015-07-08	HUMAN MONOCLONAL ANTIBODY
IL228403A0 (en)	2013-12-31	Compositions comprising anti-influenza antobodies and pseltamivir and uses thereof